RecruitingNCT04028531
Understanding Chronic Lymphocytic Leukemia
Sponsor
Dana-Farber Cancer Institute
Enrollment
2,750 participants
Start Date
Sep 29, 1999
Study Type
OBSERVATIONAL
Conditions
Summary
The purpose of this study is to collect human Chronic Lymphocytic Leukemia tissue samples and medical information, in order to find out more about the causes and biology of chronic lymphocytic leukemia.
Eligibility
Min Age: 18 Years
Plain Language Summary
Simplified for easier understanding
This is an observational study that collects information and samples from patients with chronic lymphocytic leukemia (CLL) — a slow-growing blood cancer — and related conditions, to help researchers better understand how these diseases develop and respond to treatment over time.
**You may be eligible if...**
- You have been diagnosed with chronic lymphocytic leukemia (CLL), monoclonal B-cell lymphocytosis (a precursor condition), or another low-grade lymphoproliferative disorder (a slow-growing blood cell condition)
- You are seen for treatment at Dana-Farber Cancer Institute or elsewhere
**You may NOT be eligible if...**
- There are no formal exclusion criteria listed for this study
Talk to your doctor to see if this trial is right for you.
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04028531
Related Trials
AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON Database
NCT065481521 location
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
NCT07321652141 locations
Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus
NCT072885151 location
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
NCT04269902628 locations
A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies
NCT0727166711 locations